Investors Overview

Crescita (TSX:CTX) is a publicly traded, Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions and diseases and their associated symptoms. Crescita owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active drugs into or through the skin. Crescita’s portfolio also includes Pliaglis, our lead prescription product, that utilizes our proprietary phase-changing topical cream Peel technology. The product is approved in 37 countries and licensed to seven commercial partners for sale in 39 countries. We market Pliaglis in the Canadian physician-dispensed skincare market through our own sales force.

​

Our vision is to become a leader in innovative, science-based skincare solutions, providing improved outcomes for all our clients’ skincare concerns. Our corporate growth strategy is comprised of four pillars, each of which is based on the fundamentals of our business model. Together, we refer to these as our “Four-Pillar Growth Strategy.”

​

Pillar 1: Organic Growth

Pillar 2: Strategic Acquisitions and/or In-licensing Agreements

Pillar 3: Strategic Out-licensing of Assets

Pillar 4: Contract Development and Manufacturing Services